Rznomics Inc. Gains Approval in Australia for Clinical Trial of RNA Editing Therapy Targeting RHO Gene in Retinitis Pigmentosa.

Cytonics Reveals Start Of Initial Human Phase 1 Trial For CYT-108 In Individuals With Knee Osteoarthritis.

Ferring Reveals Initial Findings From Key Phase 3 Study on SI-6603 (condoliase) for Lumbar Disc Herniation at ASPN 2024.

Lexeo Therapeutics Shares Encouraging Early Phase 1/2 Results of LX2006 for Friedreich Ataxia Cardiomyopathy Treatment.

Camurus reveals successful Phase 3 outcomes for the ACROINNOVA 2 trial of octreotide SC depot (CAM2029) in individuals with acromegaly.

AbbVie Files for Regulatory Approval of Upadacitinib (RINVOQ®) with FDA and EMA for Treatment of Giant Cell Arteritis.

YolTech Therapeutics has announced the successful enrollment of the inaugural patient in the Phase I clinical trial of YOLT-201.

Olatec Therapeutics, Inc., a pioneer in the field of selective NLRP3 inhibitors, revealed that individuals with type 2 diabetes mellitus and associated diabetic complications are currently being recruited

Vivani Medical, Inc., a pioneering company in biopharmaceuticals, revealed plans to commence the inaugural clinical trial for the NPM-115 initiative in Australia.

Pfizer have chosen the preferred once-daily modified release form of danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist.

This submission seeks regulatory approval through the Therapeutic Goods Administration (TGA)’s Clinical Trial Notification scheme to initiate a first-in-human Phase 1 clinical trial for SAT-3247.

Context Therapeutics Inc. has publicized the acquisition of CT-95, previously the property of Link Immunotherapeutics, Inc.